Astellas acquired Mainz, Germany-based Ganymed Pharmaceuticals for EUR 422M (~$463M) upfront plus up to EUR 860M (~$937M) in contingent payments tied to IMAB362 development progress (~EUR 1.282B / $1.4B total). Lead asset IMAB362 (later zolbetuximab) is an anti-Claudin 18.2 monoclonal antibody in Phase 2b for gastric/GEJ cancer. Closed December 20, 2016. FDA-approved as Vyloy in October 2024.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Neutral
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedOct 28, 2016
ClosedDec 20, 2016
Deal value$1.4B
Deal typeAcquisition/Merger
Therapeutic areaClaudin 18.2-positive gastric and gastroesophageal junction (GEJ) adenocarcinoma
IndicationsClaudin 18.2-positive gastric and gastroesophageal junction (GEJ) adenocarcinoma